0001209191-17-006410.txt : 20170131 0001209191-17-006410.hdr.sgml : 20170131 20170131165547 ACCESSION NUMBER: 0001209191-17-006410 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20170127 FILED AS OF DATE: 20170131 DATE AS OF CHANGE: 20170131 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Cascadian Therapeutics, Inc. CENTRAL INDEX KEY: 0001412067 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-COMMERCIAL PHYSICAL & BIOLOGICAL RESEARCH [8731] IRS NUMBER: 260868560 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 2601 FOURTH AVENUE STREET 2: SUITE 500 CITY: SEATTLE STATE: WA ZIP: 98121 BUSINESS PHONE: (206) 801-2100 MAIL ADDRESS: STREET 1: 2601 FOURTH AVENUE STREET 2: SUITE 500 CITY: SEATTLE STATE: WA ZIP: 98121 FORMER COMPANY: FORMER CONFORMED NAME: Oncothyreon Inc. DATE OF NAME CHANGE: 20070927 FORMER COMPANY: FORMER CONFORMED NAME: Biomira CORP DATE OF NAME CHANGE: 20070911 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Myers Scott Dunseth CENTRAL INDEX KEY: 0001356256 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-33882 FILM NUMBER: 17561800 MAIL ADDRESS: STREET 1: C/O ONOTHYREON INC. STREET 2: 2601 4TH AVENUE, SUITE 500 CITY: SEATTLE STATE: WA ZIP: 98121 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2017-01-27 0 0001412067 Cascadian Therapeutics, Inc. CASC 0001356256 Myers Scott Dunseth C/O CASCADIAN THERAPEUTICS, INC. 2601 4TH AVE., SUITE 500 SEATTLE WA 98121 1 1 0 0 President and CEO Common Stock 2017-01-27 4 P 0 20500 3.758 A 38416 D The reported price in Column 4 is a weighted average price. These shares were bought in multiple transactions at prices ranging from $3.695 to $3.8435 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Effective as of November 29, 2016, the issuer effected a 6-for-1 reverse split of its common stock. The number of shares above reflects the reverse stock split. /s/ Julia M. Eastland as attorney-in-fact for Scott D. Myers 2017-01-31